2025-09-24 (三) 19:00 ~ 20:30

Join us for an expert-led exchange on biomarker-driven therapy in Non-Small Cell Lung Cancer (NSCLC), with a focus on NTRK and HER2 alterations.

This interactive session is designed to bring together lung cancer specialists to discuss the role of biomarker testing in driving treatment decisions, and to evaluate the latest data on targeted therapies, clinical trials, and real-world outcomes in NSCLC.

The use of molecular biomarkers—such as NTRK and HER2—is crucial for identifying patients who may benefit from targeted therapies that improve objective response rates (ORR) and quality of life (QoL). This program will highlight how biomarker integration into routine care can enhance treatment precision and patient outcomes, while also providing a collaborative platform for clinical insight exchange.